Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
NCT02142530Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2014
- Primary completion
- Mar 2017
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carfilzomib and belinostat in non-Hodgkin lymphoma (NHL), sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Oct 2014; status: completed.
02
Drugs
carfilzomibbelinostat
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02142530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02142530.